Claims

1. A pharmaceutical composition comprising chloroquine or a pharmaceutically acceptable salt thereof, and a solvent, wherein the pharmaceutical composition comprises 1 mg/mL to 200 mg/mL chloroquine or a pharmaceutically acceptable salt thereof, wherein the solvent is selected from propylene glycol, glycerine, propane-1,3-diol and water or combinations thereof and wherein the pharmaceutical composition is for thermal aerosolization.

2. A pharmaceutical composition according to claim 1 comprising 1 mg/mL to 50 mg/mL chloroquine or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition according to claim 1 or 2, comprising 10 mg/mL to 45 mg/mL, preferably 20 mg/mL to 40 mg/mL, more preferably 30 mg/mL to 35 mg/mL of chloroquine or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition is thermally aerosolized.

5. Use of ~~A~~a pharmaceutical composition comprising chloroquine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for ~~use in~~ the treatment or prevention of a viral lung infection, wherein the pharmaceutical composition is to be administered by oral inhalation.

6. The ~~pharmaceutical composition for~~ use according to claim 5, wherein the viral lung infection is caused by *Betacoronavirus*, for example, 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).

7. The ~~pharmaceutical composition for~~ use according to claims 5 to 6, wherein the pharmaceutical composition is to be administered as a daily dose.

8. The ~~pharmaceutical composition for~~ use according to claim 7, wherein the daily dose comprises 0.001 mg to 20 mg, preferably 0.005 mg to 15 mg, preferably 0.01 mg to 10 mg, preferably 0.05 mg to 8 mg, preferably 0.1 to 6 mg, or preferably 0.15 mg to 5 mg of chloroquine or a pharmaceutically acceptable salt thereof.

9. The ~~pharmaceutical composition for~~ use according to claim 7 or 8, wherein the daily dose is selected from a loading dose, a maintenance dose or combinations thereof.

10. The ~~pharmaceutical composition for~~ use according to claim 9, wherein the loading dose comprises 1 mg to 20 mg, preferably 2 mg to 15 mg, more preferably 3 mg to 10 mg, more preferably 4 mg to 8 mg most preferably 4.5 mg to 6 mg of chloroquine or a pharmaceutically acceptable salt thereof.

11. The ~~pharmaceutical composition for~~ use according to claim 9, wherein the maintenance

dose comprises 0.001 mg to 10 mg, preferably 0.005 mg to 9 mg, preferably 0.01 mg to 8 mg, preferably 0.05 mg to 7 mg, preferably 0.1 to 6 mg, preferably 0.15 mg to 5 mg of chloroquine or a pharmaceutically acceptable salt thereof.

12. The ~~pharmaceutical composition for~~ use according to claims 9 to 11, wherein at least one loading dose is followed by at least one maintenance dose.

13. The ~~pharmaceutical composition for~~ use according to any one of claims 7 to 12, wherein the daily dose is to be administered in at least one session.

14. The ~~pharmaceutical composition for~~ use according to claims 7 to 13 wherein the daily dose is to be administered in at least two sessions separated by intervals of twelve hours, ten hours, eight hours, seven hours, or six hours.

15. The ~~pharmaceutical composition for~~ use according to claims 13 to 14, wherein the session comprises at least one fixed dose.

16. The ~~pharmaceutical composition for~~ use according to claim 15, wherein the fixed dose is a metered dose.

17. The ~~pharmaceutical composition for~~ use according to any of claims 5 to 16, wherein the pharmaceutical composition is to be administered as a liquid aerosol.

18. The ~~pharmaceutical composition for~~ use according to claim 17, wherein the Mass Median Aerodynamic Diameter (MMAD) of the liquid aerosol is 1 to 5 µm.

19. The ~~pharmaceutical composition for~~ use according to claim 5 or 18, wherein the pharmaceutical composition is thermally aerosolized.

20. The ~~pharmaceutical composition for~~ use according to claims 5 to 19, wherein the treatment or prevention is in a mammalian or avian subject.

21. The ~~pharmaceutical composition for~~ use according to claim 20, wherein the mammalian subject is human.

22. The ~~pharmaceutical composition for~~ use according to any of claims 20 to 21, wherein the subject is at risk of having COVID-19.

23. The ~~pharmaceutical composition for~~ use according to any of claims 20 to 21, wherein the subject shows symptoms of having COVID-19.

24. The ~~pharmaceutical composition for~~ use according to any of claims 20 to 21, wherein the subject is COVID-19 positive, for example, confirmed by PCR testing.